Drug-induced secondary haemophagocytic lymphohistiocytosis in hairy cell leukaemia

J R Coll Physicians Edinb. 2024 Mar;54(1):29-33. doi: 10.1177/14782715231220108. Epub 2023 Dec 30.

Abstract

Haemophagocytic lymphohistiocytosis (HLH) is a rare, aggressive, excess immune activation syndrome. Diagnosis can be challenging due to its several clinical mimics including sepsis. There are multiple aetiologies of HLH; in adults, it is most commonly triggered by infection, malignancy, drugs and autoimmune processes. Failure to rapidly diagnose and treat this condition can be fatal. The management of HLH includes identifying and removing the trigger, supportive management and immunosuppression. Identifying the trigger is essential to inform the most appropriate type of immunosuppression. Here, we report a case of likely drug-induced HLH in a patient recently treated for hairy cell leukaemia. The culprit drug was thought to be co-trimoxazole and this case report highlights a very rare complication of this commonly used drug. We discuss our management approach with steroid monotherapy and withdrawal of co-trimoxazole.

Keywords: adverse drug reaction; co-trimoxazole; drug-induced; haemophagocytic lymphohistiocytosis; hairy cell leukaemia.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Leukemia, Hairy Cell* / complications
  • Leukemia, Hairy Cell* / drug therapy
  • Lymphohistiocytosis, Hemophagocytic* / chemically induced
  • Lymphohistiocytosis, Hemophagocytic* / diagnosis
  • Lymphohistiocytosis, Hemophagocytic* / drug therapy
  • Male
  • Middle Aged
  • Neoplasms* / complications
  • Sepsis*
  • Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects

Substances

  • Trimethoprim, Sulfamethoxazole Drug Combination